Athira Pharma appoints Dr. Michael Panzara to board effective March 18, 2022

LeonaBio, Inc.

Dr. Panzara, CMO at Wave Life Sciences, appointed Class I director with term expiring at 2024 annual meeting.
He brings over 20 years CNS drug development experience, including leadership at Sanofi Genzyme and Biogen.
Compensation includes initial stock option grant; no transactions with the company or its affiliates.
Press release notes his role in global regulatory approvals of MS drugs LEMTRADA, AUBAGIO, and TYSABRI.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael Panzara

director

LONA · LeonaBio, Inc.

Effective: 2022-03-18
Filed: March 21, 2022, 7:59 PM ET

appointed Dr. Michael Panzara as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Panzara was appointed as director at LeonaBio, Inc..

Action: appointed
Role: director

Exact text from the filing

appointed Dr. Michael Panzara as a director of the Company, effective immediately.

View on SEC.gov

LeonaBio, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-080027

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.